drugset / Trial / NCT00332852
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a prospective open-label one-arm phase III trial designed to evaluate the safety and efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in postmenopausal patients with primary breast cancer. This trial is not recruiting patients in the United States.
Timeline
- Start
- 2006-03
- Primary completion
- 2010-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |